Christopher J. Kane, MD, FACS, the Dean of Clinical Affairs at the University of California San Diego School of Medicine, and the CEO of the UC San Diego Health Physician Group, delivers an insightful presentation on surgery versus brachytherapy for intermediate and highrisk prostate cancer. He highlights the importance of accurately defining highrisk disease and presents his viewpoint that surgery is the optimal treatment for wellselected patients.